Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Melphalan and ASCT in Primary Light Chain Amyloidosis
NCT00017680Phase 2Completed
- Sponsor
- Herbert Irving Comprehensive Cancer Center
- Start
- Jul 1999
- Primary completion
- Apr 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of melphalan in AL amyloidosis (AL), sponsored by Herbert Irving Comprehensive Cancer Center. Started Jul 1999; status: completed.
02
Drugs
melphalan
03
Conditions
AL amyloidosis (AL)
Beyond the preview
Go deeper on NCT00017680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00017680.